Becker's Healthcare June 21, 2021
Katie Adams

Nearly $50 billion of Medicare Part D costs in 2016 were for drugs that did not undergo a cost-effectiveness analysis, according to a study published June 18 in JAMA Network Open.

Researchers looked at the 250 drugs with the greatest Medicare Part D spending in 2016, and found 46 percent of them did not have a cost-effectiveness...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech, Survey / Study, Trends
GOP jumps on chance to bash Biden on Medicare
Does Medicare cover physical therapy? Yes, and you might be eligible for more services, too
CMMI’s Innovations in Behavioral Health: Promoting Physical and Mental Well-being
7 Tips for making the most of value-based care
Medicare Stumbles Managing a Costly Problem — Chronic Illness

Share This Article